Go Pro
LON:OPTI

OptiBiotix Health Interim Earnings Report

OptiBiotix Health logo
GBX 5.98 -0.62 (-9.39%)
As of 12:43 PM Eastern

OptiBiotix Health EPS Results

Actual EPS
-GBX 1.52
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

OptiBiotix Health Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OptiBiotix Health Announcement Details

Quarter
Interim
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

OptiBiotix Health Earnings Headlines

OptiBiotix Health Plc H1 Loss Rises
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.tc pixel
See More OptiBiotix Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OptiBiotix Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OptiBiotix Health and other key companies, straight to your email.

About OptiBiotix Health

OptiBiotix Health (LON:OPTI) (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks. OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

View OptiBiotix Health Profile